Correspondence 0001193125-23-188707 from Turnstone Biologics Corp. (CIK 0001764974)
Turnstone Biologics Corp. (CIK 0001764974)
Date: July 18, 2023 · CIK: 0001764974 · Accession: 0001193125-23-188707
AI Filing Summary & Sentiment
File numbers found in text: 333-272600
Letter
BofA Securities, Inc.
One Bryant Park
New York, New York 10036
Leerink Partners LLC
1301 Avenue of the Americas, 12th Floor
New York, New York 10019
Piper Sandler & Co.
U.S. Bancorp Center
800 Nicollet Mall
Minneapolis, Minnesota 55402
July 18, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Lauren Hamill
Joshua Gorsky
Division of Corporation Finance
Office of Life Sciences
Re: Turnstone Biologics Corp.
Registration Statement on Form S-1
File No. 333-272600
Acceleration Request
Requested Date: July 20,
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Turnstone Biologics Corp. (the “Company”) for acceleration of the effective date of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on July 20, 2023, or at such later time as the Company or its outside counsel, Cooley LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, please be advised that we, as representatives of the several underwriters, will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
Very truly yours,
BOFA SECURITIES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP BofA Securities, Inc. One Bryant Park New York, New York 10036 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 July 18, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Hamill Joshua Gorsky Division of Corporation Finance Office of Life Sciences Re: Turnstone Biologics Corp. Registration Statement on Form S-1 File No. 333-272600 Acceleration Request Requested Date: July 20, 2023 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Turnstone Biologics Corp. (the “Company”) for acceleration of the effective date of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on July 20, 2023, or at such later time as the Company or its outside counsel, Cooley LLP, may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Pursuant to Rule 460 under the Act, please be advised that we, as representatives of the several underwriters, will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement. We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Signature Page Follows] Very truly yours, BOFA SECURITIES, INC. By: /c/ Aamir Mecklai Name: Aamir Mecklai Title: Managing Director LEERINK PARTNERS LLC By: /c/ Anurag Jindal Name: Anurag Jindal Title: Senior Managing Director PIPER SANDLER & CO. By: /c/ Neil Riley Name: Neil Riley Title: Managing Director [Signature Page to Underwriters’ Acceleration Request]